This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Care

Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results

Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results

These Achillion results aren't great because the speed at which drugs kill the hepatitis C virus matters. Slower-acting drugs leave patients vulnerable to viral rebound or relapse.

12/22/14 - 11:36 AM EST

AbbVie's Exclusive Hepatitis C Deal With Express Scripts: What Wall Street's Saying

AbbVie strikes an exclusive deal with Express Scripts to exclusively distribute AbbVie's hepatitis C therapy. Here's what analysts said.

12/22/14 - 11:20 AM EST

Try Jim Cramer's Action Alerts PLUS
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015

J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015

Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.

12/22/14 - 08:23 AM EST

December 22 Premarket Briefing: 10 Things You Should Know

December 22 Premarket Briefing: 10 Things You Should Know

U.S. stock futures rise as oil prices rebound; Express Scripts and AbbVie are in an exclusive hepatitis C pharmacy deal; Staples suffers a data breach.

12/22/14 - 06:45 AM EST

Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market

Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market

The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.

12/22/14 - 06:14 AM EST

Juno Therapeutics Debuts on the Nasdaq, Stock Soars 50%

Juno Therapeutics Debuts on the Nasdaq, Stock Soars 50%

Juno Therapeutics CEO Hans Bishop tells TheStreet's Jill Malandrino that the company is focused on improving cancer patients' treatment.

12/19/14 - 04:31 PM EST

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next

U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.

12/19/14 - 04:16 PM EST

Juno Therapeutics Debuts on the Nasdaq, Trades Higher by 60%

  • Tickers in this article:
  • JUNO

Juno Therapeutics CEO Hans Bishop tells TheStreet Juno is focused on the better treatment of patients with cancer.

12/19/14 - 12:40 PM EST

Eli Lilly and Adocia Come to $570 Million Insulin Deal

  • Tickers in this article:
  • LLY
  • ADOC

U.S. drugmaker Eli Lilly and French pharmaceutical company Adocia agree to a $570 million deal to develop a fast-acting insulin.

12/19/14 - 12:24 PM EST

Stephanie Link's Top 3 Stocks Picks in the Healthcare Space for 2015

Stephanie Link picks baskets of stocks that diversified within the sector itself and says that will be applied to her 2015 Healthcare picks.

12/19/14 - 11:00 AM EST

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.

12/19/14 - 09:02 AM EST

Rite Aid Surges on Profit Guidance: What Wall Street's Saying

Rite Aid Surges on Profit Guidance: What Wall Street's Saying

  • Tickers in this article:
  • RAD

Rite Aid shares spiked more than 12% after the drugstore chain boosted its guidance for the year. Here's what analysts said.

12/18/14 - 02:01 PM EST

The Winners for Best and Worst Biotech CEOs of 2014 Are...

The Winners for Best and Worst Biotech CEOs of 2014 Are...

Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.

12/18/14 - 10:01 AM EST

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.

12/18/14 - 09:35 AM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs